Flying The Web For News.
  • Happy Holidays
    Happy Holidays
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Zealand Pharma major shareholder announcement: Bank of America Corporation

Details
Category: Globe NewsWire News Distribution Service

Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports prior receipt on 19 March 2024 and 5…


Posted: 2024-08-16 16:05:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | zealand | pharma | major


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Zealand Pharma major shareholder announcement: Bank of America Corporation - Newscast

Zealand Pharma's Monotherapy Approach Gains Momentum Amid Obesity Drug Market Fluctuations

Fri, 20 Dec 2024 05:54:00 GMT Zealand Pharma's CEO highlighted the potential of their monotherapy approach using cagrilintide, buoyed by data from Novo Nordisk's CagriSema study. Despite immediate market setbacks, Zealand's drug, ...

BTIG Remains a Buy on Zealand Pharma (ZLDPF)

Fri, 20 Dec 2024 04:35:00 GMT Based on Zealand Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $28.37 million and a GAAP net loss of $488.5 million. In comparison, last ...

Zealand Pharma's Bold Stance Amid CagriSema Study Results

Fri, 20 Dec 2024 04:12:00 GMT Zealand Pharma CEO Adam Steensberg claims Novo Nordisk's recent CagriSema study supports their monotherapy approach with cagrilintide, despite the market's disappointment and a 20% plunge in Zealand's ...

Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide

Fri, 20 Dec 2024 00:06:00 GMT LONDON, Dec 20 (Reuters) - The CEO of Danish drugmaker Zealand Pharma (ZELA.CO), opens new tab said on Friday ... Maggie got her start in journalism in 2010 as a freelancer for The Associated Press in ...

FDA rejects Zealand Pharma's drug for short bowel syndrome

Thu, 19 Dec 2024 13:40:59 GMT Zealand Pharma (ZLDPF) said the FDA has declined to approve its drug glepaglutide for the treatment of short bowel syndrome, citing the need for more data. Read more here.


Blow Us A Whistle